What is Trodelvy? | Information & FAQ | TheSocialMedwork
Article reviewed by Dr. Jan de Witt
Article last updated on 22/1/2021
What is Trodelvy (sacituzumab govitecan-hziy)?
Trodelvy is an antibody-drug conjugate (ADC; an immune targeted therapy). It is used for the treatment of patients with metastatic triple-negative breast cancer (mTNBC), who have received at least 2 previous therapies for metastatic disease. Trodelvy is the first ADC the FDA has approved for the treatment of people with mTNBBC.1
How much does Trodelvy (sacituzumab govitecan-hziy) cost?
For more information about how much Trodelvy costs and how we can help you access it, please click on the button below:
What is Trodelvy (sacituzumab govitecan-hziy) used for?
Trodelvy is a medication used for the treatment of patients with metastatic triple-negative breast cancer (mTNBC), who have received at least 2 previous therapies for metastatic disease. TNBC accounts for up to 20% of all breast cancers.1
Trodelvy is currently also under investigation for the treatment of patients with bladder cancer or glioblastoma, an aggressive type of brain cancer.2,3
Is Trodelvy (sacituzumab govitecan-hziy) a chemotherapy?
Trodelvy is an immune targeted therapy medicine which consists of a monoclonal antibody (sacituzumab) that can help the immune system recognize and fight the cancer. Trodelvy is a so-called antibody-drug conjugate (ADC): a linking compound attaches (conjugates) sacituzumab to the SN-38 chemotherapy.1,4
What is Sacituzumab Govitecan HZIY?
Sacituzumab Govitecan is a Trop-2-directed antibody-drug conjugate (ADC). Sacituzumab Govitecan is made up of 3 parts:4
- Sacituzumab, a Trop-2-recognizing antibody, which is a type of protein designed to recognise and attach to the Trop2 antigen present on cancer cells.
- SN-38, a topoisomerase I inhibitor (chemotherapy), which damages the tumor cell’s DNA and inhibits further DNA replication.
- A compound that conjugates (links) these two parts together.
How does Trodelvy (sacituzumab govitecan-hziy) work?
When sacituzumab binds to Trop-2 on the cancer cell, the drug is taken up by the cell and the linker is broken. This causes the release of SN-38, which will then destroy the Trop-2-positive cancer cells.1,4
Who makes Trodelvy sacituzumab govitecan-hziy)?
Trodelvy is made by Immunomedics. Immunomedics is specialised in next-generation antibody-drug conjugate (ADC) technology, and they aim to help patients with hard-to-treat cancers. Trodelvy is the company's lead ADC.
What happened to Immunomedics?
On September 13, 2020, the manufacturers of Trodelvy, Gilead and Immunomedics, announced that they had signed a definitive merger agreement. Immunomedics has become a wholly owned subsidiary of Gilead. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.5
References
- Access.fda.gov
- Immunomedics.com
- Biospace.com
- Trodelvy - Breastcancer.org
- Gilead.com
- Trodelvy (sacituzumab govitecan-hziy) - Thesocialmedwork.com
